Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA : Merck Strengthens its Presence in China with New Pharmaceutical Manufacturing Facility

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/15/2013 | 08:24am CEST

Darmstadt / Germany, Nantong / China, November 15, 2013 - Merck announced today a € 80 million investment in a new pharmaceutical manufacturing facility, to be located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area).

"This further investment in China reflects Merck's long-term commitment to the country where our group has been present for 80 years," said Belén Garijo, President and Chief Executive Officer of Merck Serono, the biopharmaceutical division of Merck. "We are proud to be one of the first multinational companies investing in a local site focused on the manufacturing of medicines referenced in China's essential drug list, and serve the country's expanding healthcare needs in the areas of diabetes, cardiovascular diseases and thyroid disorders, by bringing high-quality medicines made in China to a broader population, in full alignment with the Chinese government's goal to increase access to quality products."
The new facility will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck's leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders respectively. Located in NETDA's BioSpark, a high-tech industrial park designed to accommodate all aspects of the life science industry, the new facility will cover an area of 40,000 square meters, with a possible 20,000 square meters extension. The construction of the site is scheduled to start in 2014 and to be completed in 2016, and start commercial production in 2017. The site will be designed to comply with the highest international quality standards. The preservation of the environment will also be a critical consideration in the facility's construction, with a maximization of resource efficiency and minimized waste generation during the manufacturing process.

"This new facility will become Merck Serono's second largest pharmaceutical manufacturing site in the world and will help ensure that our medicines will always be available to patients who rely on them, which is a key priority for Merck Serono," added Allan Gabor, General Manager and Managing Director of Merck Serono in China. "With our research center, our development capabilities, our commercial presence and this new manufacturing facility, we are building for the future in China by investing across our value chain."

As part of its 80-year history in China, Merck has made significant investments in the country. Over the past five years only, investments for the Merck Serono division included:
- A research center in Beijing, focused on biomarker research, including pharmacogenomics and bioanalytics, which is part of Merck Serono's stratified medicine approach;
- Enhanced clinical development capabilities, covering over 400 key clinical study sites and having recruited over 10,000 patients accumulatively across China;
- Increased commercial presence to better serve patients and healthcare providers;
- An extensive network of collaborations with leading academic and medical institutions, as well as local companies; Merck Serono's latest collaboration agreement with a Chinese company, announced on November 13, 2013, is a second co-development and commercialization agreement with BeiGene, which will further strengthen the two companies existing collaboration in oncology.
Recent investments for other divisions of the Merck group include the Merck Millipore Biopharmaceutical Technical and Training Centre and a soon to be opened Liquid Crystals manufacturing facility, both located in Shanghai.

About Merck Serono China
Headquartered in Beijing, Merck Serono China currently employs 1,250 people in the country. Merck Serono China offers a portfolio of medicines addressing some of the key rising healthcare needs of the Chinese population, including the division's leading brands serving patients with cancer (Erbitux®), infertility (Gonal-f®), as well as cardiometabolic diseases (Glucophage®, Concor®, Euthyrox®).

About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit www.merckserono.com.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
08:11a MERCK : Darmstadt, Germany Advances R&D Strategy through Unique Development Mode..
03/28 PFIZER : FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA
03/25 Merck KGaA and Pfizer break into cancer immunotherapy
03/25 Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 MERCK : Global Analyzer for Particle Counters Market- HCT Instruments, Honri, IQ..
03/23 MERCK : FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Ap..
03/23 PFIZER : FDA Grants Approval for BAVENCIO (avelumab)
03/23 PFIZER : FDA Grants Approval for BAVENCIO (avelumab), the First Immunotherapy Ap..
03/22 “BOLD & VIBRANT” : Merck KGaA, Darmstadt, Germany, Presents Innovati..
03/22 MERCK : unveils 2017 Darmstadt and Nairobi accelerator startups
More news
Sector news : Specialty & Advanced Pharmaceuticals
11:07aDJOXFORD BIOMEDICA : Hails U.S. Regulatory Boost for Leukemia Treatment
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
03/23 FDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer
03/23 BeiGene, Another Beijing Venture In Cancer Therapy
03/10 Pfizer And Merck Go For An Even Longer Throw Of The Javelin
03/09 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q4 2016 Results - Earnings Call T..
03/09 Merck KGaA 2016 Q4 - Results - Earnings Call Slides
Advertisement
Financials (€)
Sales 2017 15 583 M
EBIT 2017 3 274 M
Net income 2017 1 846 M
Debt 2017 9 671 M
Yield 2017 1,22%
P/E ratio 2017 24,33
P/E ratio 2018 20,67
EV / Sales 2017 1,49x
EV / Sales 2018 1,31x
Capitalization 13 474 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 110 €
Spread / Average Target 5,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA4.69%14 491
ABBVIE INC5.03%104 810
KYOWA HAKKO KIRIN CO L..10.01%9 226
JAZZ PHARMACEUTICALS P..33.95%8 725
CONVATEC GROUP PLC14.96%6 632
MALLINCKRODT PLC-8.53%4 771
More Results